The open-label study of the impact of dapagliflozin to the visceral fat for diabetes patients
Phase of Trial: Phase IV
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Subcutaneous fat disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 17 Feb 2017 Status changed from recruiting to completed.
- 05 Aug 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 02 Jul 2015 New trial record